-
1
-
-
0027991976
-
Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies
-
Otto CM, Kuusisto J, Reichenbach DD, Gown AM, O'Brien KD. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation. 1994;90:844-853.
-
(1994)
Circulation
, vol.90
, pp. 844-853
-
-
Otto, C.M.1
Kuusisto, J.2
Reichenbach, D.D.3
Gown, A.M.4
O'Brien, K.D.5
-
2
-
-
0033057678
-
Identification and characterization of calcifying valve cells from human and canine aortic valves
-
Mohler ER III, Chawla MK, Chang AW, Vyavahare N, Levy RJ, Graham L, Gannon FH. Identification and characterization of calcifying valve cells from human and canine aortic valves. J Heart Valve Dis. 1999;8:254-260.
-
(1999)
J Heart Valve Dis
, vol.8
, pp. 254-260
-
-
Mohler Iii, E.R.1
Chawla, M.K.2
Chang, A.W.3
Vyavahare, N.4
Levy, R.J.5
Graham, L.6
Gannon, F.H.7
-
3
-
-
0038711036
-
Human aortic valve calcification is associated with an osteoblast phenotype
-
Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, Springett M, Orszulak T, Fullerton DA, Tajik AJ, Bonow RO, Spelsberg T. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation. 2003;107:2181-2184.
-
(2003)
Circulation
, vol.107
, pp. 2181-2184
-
-
Rajamannan, N.M.1
Subramaniam, M.2
Rickard, D.3
Stock, S.R.4
Donovan, J.5
Springett, M.6
Orszulak, T.7
Fullerton, D.A.8
Tajik, A.J.9
Bonow, R.O.10
Spelsberg, T.11
-
4
-
-
0027285583
-
Bone morphogenetic protein expression in human atherosclerotic lesions
-
Boström K, Watson KE, Horn S, Wortham C, Herman IM, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809.
-
(1993)
J Clin Invest
, vol.91
, pp. 1800-1809
-
-
Boström, K.1
Watson, K.E.2
Horn, S.3
Wortham, C.4
Herman, I.M.5
Demer, L.L.6
-
5
-
-
79952337610
-
Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: An update
-
Wang N, Yin R, Liu Y, Mao G, Xi F. Role of peroxisome proliferator-activated receptor-γ in atherosclerosis: an update. Circ J. 2011;75:528-535.
-
(2011)
Circ J
, vol.75
, pp. 528-535
-
-
Wang, N.1
Yin, R.2
Liu, Y.3
Mao, G.4
Xi, F.5
-
6
-
-
83655167182
-
Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice
-
Qu A, Shah YM, Manna SK, Gonzalez FJ. Disruption of endothelial peroxisome proliferator-activated receptor γ accelerates diet-induced atherogenesis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol. 2012;32:65-73.
-
(2012)
Arterioscler Thromb Vasc Biol
, vol.32
, pp. 65-73
-
-
Qu, A.1
Shah, Y.M.2
Manna, S.K.3
Gonzalez, F.J.4
-
7
-
-
63449116245
-
Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling
-
Meredith D, Panchatcharam M, Miriyala S, Tsai YS, Morris AJ, Maeda N, Stouffer GA, Smyth SS. Dominant-negative loss of PPARgamma function enhances smooth muscle cell proliferation, migration, and vascular remodeling. Arterioscler Thromb Vasc Biol. 2009;29:465-471.
-
(2009)
Arterioscler Thromb Vasc Biol
, vol.29
, pp. 465-471
-
-
Meredith, D.1
Panchatcharam, M.2
Miriyala, S.3
Tsai, Y.S.4
Morris, A.J.5
Maeda, N.6
Stouffer, G.A.7
Smyth, S.S.8
-
8
-
-
23244451031
-
Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice
-
Babaev VR, Yancey PG, Ryzhov SV, Kon V, Breyer MD, Magnuson MA, Fazio S, Linton MF. Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2005;25:1647-1653.
-
(2005)
Arterioscler Thromb Vasc Biol
, vol.25
, pp. 1647-1653
-
-
Babaev, V.R.1
Yancey, P.G.2
Ryzhov, S.V.3
Kon, V.4
Breyer, M.D.5
Magnuson, M.A.6
Fazio, S.7
Linton, M.F.8
-
9
-
-
21044441395
-
Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells
-
Kawaguchi H, Akune T, Yamaguchi M, Ohba S, Ogata N, Chung UI, Kubota N, Terauchi Y, Kadowaki T, Nakamura K. Distinct effects of PPARgamma insufficiency on bone marrow cells, osteoblasts, and osteoclastic cells. J Bone Miner Metab. 2005;23:275-279.
-
(2005)
J Bone Miner Metab
, vol.23
, pp. 275-279
-
-
Kawaguchi, H.1
Akune, T.2
Yamaguchi, M.3
Ohba, S.4
Ogata, N.5
Chung, U.I.6
Kubota, N.7
Terauchi, Y.8
Kadowaki, T.9
Nakamura, K.10
-
10
-
-
33745839778
-
Transient suppression of PPARgamma directed ES cells into an osteoblastic lineage
-
Yamashita A, Takada T, Nemoto K, Yamamoto G, Torii R. Transient suppression of PPARgamma directed ES cells into an osteoblastic lineage. FEBS Lett. 2006;580:4121-4125.
-
(2006)
FEBS Lett
, vol.580
, pp. 4121-4125
-
-
Yamashita, A.1
Takada, T.2
Nemoto, K.3
Yamamoto, G.4
Torii, R.5
-
11
-
-
0035882483
-
Oxidative stress modulates osteoblastic differentiation of vascular and bone cells
-
Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med. 2001;31:509-519.
-
(2001)
Free Radic Biol Med
, vol.31
, pp. 509-519
-
-
Mody, N.1
Parhami, F.2
Sarafian, T.A.3
Demer, L.L.4
-
12
-
-
36549023457
-
Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification
-
Shao JS, Aly ZA, Lai CF, Cheng SL, Cai J, Huang E, Behrmann A, Towler DA. Vascular Bmp Msx2 Wnt signaling and oxidative stress in arterial calcification. Ann N Y Acad Sci. 2007;1117:40-50.
-
(2007)
Ann N y Acad Sci
, vol.1117
, pp. 40-50
-
-
Shao, J.S.1
Aly, Z.A.2
Lai, C.F.3
Cheng, S.L.4
Cai, J.5
Huang, E.6
Behrmann, A.7
Towler, D.A.8
-
13
-
-
49849089138
-
Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans
-
Miller JD, Chu Y, Brooks RM, Richenbacher WE, Peña-Silva R, Heistad DD. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol. 2008;52:843-850.
-
(2008)
J Am Coll Cardiol
, vol.52
, pp. 843-850
-
-
Miller, J.D.1
Chu, Y.2
Brooks, R.M.3
Richenbacher, W.E.4
Peña-Silva, R.5
Heistad, D.D.6
-
14
-
-
67249120424
-
Lowering plasma cholesterol levels halts progression of aortic valve disease in mice
-
Miller JD, Weiss RM, Serrano KM, Brooks RM II, Berry CJ, Zimmerman K, Young SG, Heistad DD. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation. 2009;119:2693-2701.
-
(2009)
Circulation
, vol.119
, pp. 2693-2701
-
-
Miller, J.D.1
Weiss, R.M.2
Serrano, K.M.3
Brooks, I.I.R.M.4
Berry, C.J.5
Zimmerman, K.6
Young, S.G.7
Heistad, D.D.8
-
15
-
-
33750703971
-
Calcific aortic valve stenosis in old hypercholesterolemic mice
-
Weiss RM, Ohashi M, Miller JD, Young SG, Heistad DD. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation. 2006;114:2065-2069.
-
(2006)
Circulation
, vol.114
, pp. 2065-2069
-
-
Weiss, R.M.1
Ohashi, M.2
Miller, J.D.3
Young, S.G.4
Heistad, D.D.5
-
16
-
-
78650382469
-
Evidence for active regulation of pro-osteogenic signaling in advanced aortic valve disease
-
Miller JD, Weiss RM, Serrano KM, Castaneda LE, Brooks RM, Zimmerman K, Heistad DD. Evidence for active regulation of pro-osteogenic signaling in advanced aortic valve disease. Arterioscler Thromb Vasc Biol. 2010;30:2482-2486.
-
(2010)
Arterioscler Thromb Vasc Biol
, vol.30
, pp. 2482-2486
-
-
Miller, J.D.1
Weiss, R.M.2
Serrano, K.M.3
Castaneda, L.E.4
Brooks, R.M.5
Zimmerman, K.6
Heistad, D.D.7
-
17
-
-
0031886864
-
The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation
-
Ricote M, Li AC, Willson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 1998;391:79-82.
-
(1998)
Nature
, vol.391
, pp. 79-82
-
-
Ricote, M.1
Li, A.C.2
Willson, T.M.3
Kelly, C.J.4
Glass, C.K.5
-
18
-
-
33646524699
-
Peroxisome proliferator-activated receptors and inflammation
-
Moraes LA, Piqueras L, Bishop-Bailey D. Peroxisome proliferator-activated receptors and inflammation. Pharmacol Ther. 2006;110:371-385.
-
(2006)
Pharmacol Ther
, vol.110
, pp. 371-385
-
-
Moraes, L.A.1
Piqueras, L.2
Bishop-Bailey, D.3
-
19
-
-
77649134985
-
Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome proliferator-activated receptor gamma in mouse aorta
-
Keen HL, Halabi CM, Beyer AM, de Lange WJ, Liu X, Maeda N, Faraci FM, Casavant TL, Sigmund CD. Bioinformatic analysis of gene sets regulated by ligand-activated and dominant-negative peroxisome proliferator-activated receptor gamma in mouse aorta. Arterioscler Thromb Vasc Biol. 2010;30:518-525.
-
(2010)
Arterioscler Thromb Vasc Biol
, vol.30
, pp. 518-525
-
-
Keen, H.L.1
Halabi, C.M.2
Beyer, A.M.3
De Lange, W.J.4
Liu, X.5
Maeda, N.6
Faraci, F.M.7
Casavant, T.L.8
Sigmund, C.D.9
-
20
-
-
79958147911
-
Calcific aortic valve stenosis: Methods, models, and mechanisms
-
Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res. 2011;108:1392-1412.
-
(2011)
Circ Res
, vol.108
, pp. 1392-1412
-
-
Miller, J.D.1
Weiss, R.M.2
Heistad, D.D.3
-
21
-
-
79953232077
-
ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance
-
DeFronzo RA, Tripathy D, Schwenke DC, et al.; ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011;364:1104-1115.
-
(2011)
N Engl J Med
, vol.364
, pp. 1104-1115
-
-
Defronzo, R.A.1
Tripathy, D.2
Schwenke, D.C.3
-
22
-
-
33744741007
-
Osteogenic regulation of vascular calcification
-
Towler DA, Shao JS, Cheng SL, Pingsterhaus JM, Loewy AP. Osteogenic regulation of vascular calcification. Ann N Y Acad Sci. 2006;1068:327-333.
-
(2006)
Ann N y Acad Sci
, vol.1068
, pp. 327-333
-
-
Towler, D.A.1
Shao, J.S.2
Cheng, S.L.3
Pingsterhaus, J.M.4
Loewy, A.P.5
-
23
-
-
0037314551
-
Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts
-
Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, Blomme EA. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol. 2003;199:221-228.
-
(2003)
J Pathol
, vol.199
, pp. 221-228
-
-
Duan, W.R.1
Garner, D.S.2
Williams, S.D.3
Funckes-Shippy, C.L.4
Spath, I.S.5
Blomme, E.A.6
-
24
-
-
0037432295
-
Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion
-
Lieu HD, Withycombe SK, Walker Q, Rong JX, Walzem RL, Wong JS, Hamilton RL, Fisher EA, Young SG. Eliminating atherogenesis in mice by switching off hepatic lipoprotein secretion. Circulation. 2003;107:1315-1321.
-
(2003)
Circulation
, vol.107
, pp. 1315-1321
-
-
Lieu, H.D.1
Withycombe, S.K.2
Walker, Q.3
Rong, J.X.4
Walzem, R.L.5
Wong, J.S.6
Hamilton, R.L.7
Fisher, E.A.8
Young, S.G.9
-
25
-
-
0036122331
-
Quantification of mRNA for endothelial NO synthase in mouse blood vessels by real-time polymerase chain reaction
-
Chu Y, Heistad DD, Knudtson KL, Lamping KG, Faraci FM. Quantification of mRNA for endothelial NO synthase in mouse blood vessels by real-time polymerase chain reaction. Arterioscler Thromb Vasc Biol. 2002;22:611-616.
-
(2002)
Arterioscler Thromb Vasc Biol
, vol.22
, pp. 611-616
-
-
Chu, Y.1
Heistad, D.D.2
Knudtson, K.L.3
Lamping, K.G.4
Faraci, F.M.5
-
26
-
-
33646417915
-
Serum amyloid A: The "other" inflammatory protein
-
O'Brien KD, Chait A. Serum amyloid A: the "other" inflammatory protein. Curr Atheroscler Rep. 2006;8:62-68.
-
(2006)
Curr Atheroscler Rep
, vol.8
, pp. 62-68
-
-
O'Brien, K.D.1
Chait, A.2
-
27
-
-
0032540325
-
Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma
-
Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 1998;93:229-240.
-
(1998)
Cell
, vol.93
, pp. 229-240
-
-
Nagy, L.1
Tontonoz, P.2
Alvarez, J.G.3
Chen, H.4
Evans, R.M.5
-
28
-
-
0032540012
-
PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL
-
Tontonoz P, Nagy L, Alvarez JG, Thomazy VA, Evans RM. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241-252.
-
(1998)
Cell
, vol.93
, pp. 241-252
-
-
Tontonoz, P.1
Nagy, L.2
Alvarez, J.G.3
Thomazy, V.A.4
Evans, R.M.5
-
29
-
-
0033864582
-
Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice
-
Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest. 2000;106:523-531.
-
(2000)
J Clin Invest
, vol.106
, pp. 523-531
-
-
Li, A.C.1
Brown, K.K.2
Silvestre, M.J.3
Willson, T.M.4
Palinski, W.5
Glass, C.K.6
-
30
-
-
67049159400
-
Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone
-
Nakaya H, Summers BD, Nicholson AC, Gotto AM Jr, Hajjar DP, Han J. Atherosclerosis in LDLR-knockout mice is inhibited, but not reversed, by the PPARgamma ligand pioglitazone. Am J Pathol. 2009;174:2007-2014.
-
(2009)
Am J Pathol
, vol.174
, pp. 2007-2014
-
-
Nakaya, H.1
Summers, B.D.2
Nicholson, A.C.3
Gotto Jr., A.M.4
Hajjar, D.P.5
Han, J.6
-
31
-
-
78651379500
-
Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis
-
Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
-
(2011)
N Engl J Med
, vol.364
, pp. 127-135
-
-
Khera, A.V.1
Cuchel, M.2
De La Llera-Moya, M.3
Rodrigues, A.4
Burke, M.F.5
Jafri, K.6
French, B.C.7
Phillips, J.A.8
Mucksavage, M.L.9
Wilensky, R.L.10
Mohler, E.R.11
Rothblat, G.H.12
Rader, D.J.13
-
32
-
-
67651123071
-
CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages
-
Bujold K, Rhainds D, Jossart C, Febbraio M, Marleau S, Ong H. CD36-mediated cholesterol efflux is associated with PPARgamma activation via a MAPK-dependent COX-2 pathway in macrophages. Cardiovasc Res. 2009;83:457-464.
-
(2009)
Cardiovasc Res
, vol.83
, pp. 457-464
-
-
Bujold, K.1
Rhainds, D.2
Jossart, C.3
Febbraio, M.4
Marleau, S.5
Ong, H.6
-
33
-
-
0015156452
-
Ultrastructural study of calcification of human aortic valve
-
Kim KM, Huang SN. Ultrastructural study of calcification of human aortic valve. Lab Invest. 1971;25:357-366.
-
(1971)
Lab Invest
, vol.25
, pp. 357-366
-
-
Kim, K.M.1
Huang, S.N.2
-
34
-
-
0034968385
-
Arterial calcification: A review of mechanisms, animal models, and the prospects for therapy
-
Wallin R, Wajih N, Greenwood GT, Sane DC. Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev. 2001;21:274-301.
-
(2001)
Med Res Rev
, vol.21
, pp. 274-301
-
-
Wallin, R.1
Wajih, N.2
Greenwood, G.T.3
Sane, D.C.4
-
35
-
-
0028903234
-
Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques
-
Bennett MR, Evan GI, Schwartz SM. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J Clin Invest. 1995;95:2266-2274.
-
(1995)
J Clin Invest
, vol.95
, pp. 2266-2274
-
-
Bennett, M.R.1
Evan, G.I.2
Schwartz, S.M.3
-
36
-
-
0037314647
-
Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis
-
discussion 465
-
Jian B, Narula N, Li QY, Mohler ER III, Levy RJ. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg. 2003;75:457-465; discussion 465.
-
(2003)
Ann Thorac Surg
, vol.75
, pp. 457-465
-
-
Jian, B.1
Narula, N.2
Li, Q.Y.3
Mohler Iii, E.R.4
Levy, R.J.5
-
37
-
-
79955532876
-
Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis
-
Werner C, Gensch C, Pöss J, Haendeler J, Böhm M, Laufs U. Pioglitazone activates aortic telomerase and prevents stress-induced endothelial apoptosis. Atherosclerosis. 2011;216:23-34.
-
(2011)
Atherosclerosis
, vol.216
, pp. 23-34
-
-
Werner, C.1
Gensch, C.2
Pöss, J.3
Haendeler, J.4
Böhm, M.5
Laufs, U.6
-
38
-
-
0035182469
-
Time course of osteopontin, osteocalcin, and osteonectin accumulation and calcification after acute vessel wall injury
-
Gadeau AP, Chaulet H, Daret D, Kockx M, Daniel-Lamazière JM, Desgranges C. Time course of osteopontin, osteocalcin, and osteonectin accumulation and calcification after acute vessel wall injury. J Histochem Cytochem. 2001;49:79-86.
-
(2001)
J Histochem Cytochem
, vol.49
, pp. 79-86
-
-
Gadeau, A.P.1
Chaulet, H.2
Daret, D.3
Kockx, M.4
Daniel-Lamazière, J.M.5
Desgranges, C.6
-
39
-
-
35848933241
-
Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice
-
Thorp E, Kuriakose G, Shah YM, Gonzalez FJ, Tabas I. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice. Circulation. 2007;116:2182-2190.
-
(2007)
Circulation
, vol.116
, pp. 2182-2190
-
-
Thorp, E.1
Kuriakose, G.2
Shah, Y.M.3
Gonzalez, F.J.4
Tabas, I.5
-
40
-
-
84874390188
-
-
Submitted
-
Weiss RM, Lund DD, Chu Y, Brooks RM, Zimmerman KA, El Accaoui R, Davis MK, Hajj GP, Heistad DD. Osteoprotegerin inhibits aortic valve calcification and preserves valve function in hypercholesterolemic mice. Submitted.
-
Osteoprotegerin Inhibits Aortic Valve Calcification and Preserves Valve Function in Hypercholesterolemic Mice
-
-
Weiss, R.M.1
Lund, D.D.2
Chu, Y.3
Brooks, R.M.4
Zimmerman, K.A.5
El Accaoui, R.6
Davis, M.K.7
Hajj, G.P.8
Heistad, D.D.9
-
41
-
-
79955034448
-
Transcriptional regulation of bone formation
-
Baek WY, Kim JE. Transcriptional regulation of bone formation. Front Biosci (Schol Ed). 2011;3:126-135.
-
(2011)
Front Biosci (Schol Ed)
, vol.3
, pp. 126-135
-
-
Baek, W.Y.1
Kim, J.E.2
-
42
-
-
17644380642
-
Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves
-
Simmons CA, Grant GR, Manduchi E, Davies PF. Spatial heterogeneity of endothelial phenotypes correlates with side-specific vulnerability to calcification in normal porcine aortic valves. Circ Res. 2005;96:792-799.
-
(2005)
Circ Res
, vol.96
, pp. 792-799
-
-
Simmons, C.A.1
Grant, G.R.2
Manduchi, E.3
Davies, P.F.4
-
43
-
-
75149144852
-
Hypercholesterolemia induces side-specific phenotypic changes and peroxisome proliferator-activated receptor-gamma pathway activation in swine aortic valve endothelium
-
Guerraty MA, Grant GR, Karanian JW, Chiesa OA, Pritchard WF, Davies PF. Hypercholesterolemia induces side-specific phenotypic changes and peroxisome proliferator-activated receptor-gamma pathway activation in swine aortic valve endothelium. Arterioscler Thromb Vasc Biol. 2010;30:225-231.
-
(2010)
Arterioscler Thromb Vasc Biol
, vol.30
, pp. 225-231
-
-
Guerraty, M.A.1
Grant, G.R.2
Karanian, J.W.3
Chiesa, O.A.4
Pritchard, W.F.5
Davies, P.F.6
-
44
-
-
80052329754
-
Discovery of shear-and side-specific mRNAs and miRNAs in human aortic valvular endothelial cells
-
Holliday CJ, Ankeny RF, Jo H, Nerem RM. Discovery of shear-and side-specific mRNAs and miRNAs in human aortic valvular endothelial cells. Am J Physiol Heart Circ Physiol. 2011;301:H856-H867.
-
(2011)
Am J Physiol Heart Circ Physiol
, vol.301
-
-
Holliday, C.J.1
Ankeny, R.F.2
Jo, H.3
Nerem, R.M.4
-
45
-
-
0024370924
-
Osteocalcin and matrix Gla protein: Vitamin K-dependent proteins in bone
-
Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol Rev. 1989;69:990-1047.
-
(1989)
Physiol Rev
, vol.69
, pp. 990-1047
-
-
Hauschka, P.V.1
Lian, J.B.2
Cole, D.E.3
Gundberg, C.M.4
-
46
-
-
33847014811
-
Aortic valve calcification: Determinants and progression in the population
-
Messika-Zeitoun D, Bielak LF, Peyser PA, Sheedy PF, Turner ST, Nkomo VT, Breen JF, Maalouf J, Scott C, Tajik AJ, Enriquez-Sarano M. Aortic valve calcification: determinants and progression in the population. Arterioscler Thromb Vasc Biol. 2007;27:642-648.
-
(2007)
Arterioscler Thromb Vasc Biol
, vol.27
, pp. 642-648
-
-
Messika-Zeitoun, D.1
Bielak, L.F.2
Peyser, P.A.3
Sheedy, P.F.4
Turner, S.T.5
Nkomo, V.T.6
Breen, J.F.7
Maalouf, J.8
Scott, C.9
Tajik, A.J.10
Enriquez-Sarano, M.11
-
47
-
-
21044437380
-
Spectrum of calcific aortic valve disease: Pathogenesis, disease progression, and treatment strategies
-
Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: pathogenesis, disease progression, and treatment strategies. Circulation. 2005;111:3316-3326.
-
(2005)
Circulation
, vol.111
, pp. 3316-3326
-
-
Freeman, R.V.1
Otto, C.M.2
-
48
-
-
20344364674
-
Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis
-
Scottish Aortic Stenosis Lipid Lowering Trial
-
Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med. 2005;352:2389-2397.
-
(2005)
N Engl J Med
, vol.352
, pp. 2389-2397
-
-
Cowell, S.J.1
Newby, D.E.2
Prescott, R.J.3
Bloomfield, P.4
Reid, J.5
Northridge, D.B.6
Boon, N.A.7
-
49
-
-
52649120889
-
SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
-
Rossebø AB, Pedersen TR, Boman K, et al.; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359:1343-1356.
-
(2008)
N Engl J Med
, vol.359
, pp. 1343-1356
-
-
Rossebø, A.B.1
Pedersen, T.R.2
Boman, K.3
-
50
-
-
74949091630
-
ASTRONOMER Investigators Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: Results of the aortic stenosis progression observation: Measuring effects of rosuvastatin (ASTRONOMER) trial
-
Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation. 2010;121:306-314.
-
(2010)
Circulation
, vol.121
, pp. 306-314
-
-
Chan, K.L.1
Teo, K.2
Dumesnil, J.G.3
Ni, A.4
Tam, J.5
-
51
-
-
14044262240
-
Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation
-
Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005;111:920-925.
-
(2005)
Circulation
, vol.111
, pp. 920-925
-
-
Roberts, W.C.1
Ko, J.M.2
-
53
-
-
84855405202
-
A second chance for a PPARγ targeted therapy?
-
Norris AW, Sigmund CD. A second chance for a PPARγ targeted therapy? Circ Res. 2012;110:8-11.
-
(2012)
Circ Res
, vol.110
, pp. 8-11
-
-
Norris, A.W.1
Sigmund, C.D.2
-
54
-
-
34648832073
-
Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: A meta-analysis of randomised clinical trials
-
Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007;370:1129-1136.
-
(2007)
Lancet
, vol.370
, pp. 1129-1136
-
-
Lago, R.M.1
Singh, P.P.2
Nesto, R.W.3
-
55
-
-
0036833805
-
A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes
-
St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, Patel J, Freed M. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care. 2002;25:2058-2064.
-
(2002)
Diabetes Care
, vol.25
, pp. 2058-2064
-
-
St John Sutton, M.1
Rendell, M.2
Dandona, P.3
Dole, J.F.4
Murphy, K.5
Patwardhan, R.6
Patel, J.7
Freed, M.8
-
56
-
-
34548580881
-
Long-term risk of cardiovascular events with rosiglitazone: A meta-analysis
-
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007;298:1189-1195.
-
(2007)
JAMA
, vol.298
, pp. 1189-1195
-
-
Singh, S.1
Loke, Y.K.2
Furberg, C.D.3
-
57
-
-
77951601655
-
Thiazolidinedione drugs and cardiovascular risks: A science advisory from the American Heart Association and American College of Cardiology Foundation
-
Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010;121:1868-1877.
-
(2010)
Circulation
, vol.121
, pp. 1868-1877
-
-
Kaul, S.1
Bolger, A.F.2
Herrington, D.3
Giugliano, R.P.4
Eckel, R.H.5
-
58
-
-
26244453309
-
PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): A randomised controlled trial
-
Dormandy JA, Charbonnel B, Eckland DJ, et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-1289.
-
(2005)
Lancet
, vol.366
, pp. 1279-1289
-
-
Dormandy, J.A.1
Charbonnel, B.2
Eckland, D.J.3
-
59
-
-
33847675510
-
PROactive Investigators the effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: Results from the PROactive (PROactive 05) Study
-
Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol. 2007;49:1772-1780.
-
(2007)
J Am Coll Cardiol
, vol.49
, pp. 1772-1780
-
-
Erdmann, E.1
Dormandy, J.A.2
Charbonnel, B.3
Massi-Benedetti, M.4
Moules, I.K.5
Skene, A.M.6
-
60
-
-
77954988618
-
Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone
-
Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA. 2010;304:411-418.
-
(2010)
JAMA
, vol.304
, pp. 411-418
-
-
Graham, D.J.1
Ouellet-Hellstrom, R.2
MacUrdy, T.E.3
Ali, F.4
Sholley, C.5
Worrall, C.6
Kelman, J.A.7
|